Effectiveness of Hydroxychloroquine in Covid-19 Patients

• Status: Not yet recruiting
• Trial end date: 2020-06-28
• Target enrollment: 0
• Participant gender: All

Summary

To find the effectiveness of hydroxychloroquine alone and adjuvant with azithromycin in mild to severe Covide-19 pneumonia patients admitted to Coronavirus cell/ward of Ayub Teaching hospital, Abbottabad Pakistan. A single centered, single-blind randomized control trial study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prof. Dr. Umar Farooq
• Collaborator: Ayub Medical College, Abbottabad
• Treatments: Azithromycin; Hydroxychloroquine

Criteria

Inclusion Criteria:

• Confirmed cases of Covid-19 (all by RT-PCR from same laboratory)

• Mild to severe clinical presentation (identified at the time of admission to ward by National Early Warning Score NEWS-2; mild 0-4; severe 5-6)

Exclusion Criteria:

• Covid-19 critically ill patients (NEWS-2 score <7),

• Unable to take oral medication,

• Immunocompromised,

• Creatinine clearance (CCL) < 30 ml/min,

• Aspartate transaminase (AST) or alanine transaminase (ALT) > 5 times Upper limit of normal (ULN),

• d-dimer > 2microgram per liter, or

• Known comorbid condition like hypertension, cardiovascular disease, diabetes mellites, asthma, COPD, cerebrovascular disorder, malignancy of any type, pregnancy,

• BMI less than 18

• Smoking history (one pack per day) for past six months